Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

HER2-positive Breast Cancer Project Initiated by Investigators

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Injection of A166

First Posted Date: 2022-04-26

Last Posted Date: 2022-04-26

Lead Sponsor: Fudan University

Target Recruit Count: 48

Registration Number: NCT05346328

Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

Phase 2

Not yet recruiting

Conditions: Pancreatic Neuroendocrine Neoplasm

Interventions: Drug: Nimotuzumab

First Posted Date: 2022-04-07

Last Posted Date: 2022-04-07

Lead Sponsor: Fudan University

Target Recruit Count: 42

Registration Number: NCT05316480

Locations: 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

Phase 2

Conditions: Hepatocarcinoma

Interventions: Drug: HAIC+TQB2450+Anlotinib

First Posted Date: 2022-04-05

Last Posted Date: 2022-04-05

Lead Sponsor: Fudan University

Target Recruit Count: 70

Registration Number: NCT05311319

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: H101
Drug: Tislelizumab
Drug: lenvatinib

First Posted Date: 2022-03-31

Last Posted Date: 2023-06-27

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT05303090

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)

Phase 2

Recruiting

Conditions: Pancretic Cancer
Diabete Mellitus

Interventions: Drug: Metformin or insulin treatment

First Posted Date: 2022-03-31

Last Posted Date: 2024-06-06

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT05306028

Locations: 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Phase 1

Recruiting

Conditions: Refractory Malignant Ascites

Interventions: Drug: H101
Drug: Tislelizumab

First Posted Date: 2022-03-31

Last Posted Date: 2023-04-12

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT05303844

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy

Phase 2

Conditions: Metastatic Breast Cancer in the Liver

Interventions: Combination Product: Cryoablation Combined with Tirelizumab and Bevacizumab

First Posted Date: 2022-03-31

Last Posted Date: 2022-06-09

Lead Sponsor: Fudan University

Target Recruit Count: 15

Registration Number: NCT05303038

Locations: 🇨🇳
Fudan University Shangshai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Serratus Anterior Plane Block for Modified Radical Mastectomy: Double-point VS Single-point

Not Applicable

Completed

Conditions: Serratus Anterior Plane Block
Mammary Cancer
Postoperative Pain

Interventions: Procedure: Double-point SAPB
Procedure: Single-point SAPB

First Posted Date: 2022-03-28

Last Posted Date: 2024-03-06

Lead Sponsor: Fudan University

Target Recruit Count: 57

Registration Number: NCT05299021

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

ZR-CHOP in DLBCL With Specific Gene Abnormality

Phase 2

Recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: zanubrutinib

First Posted Date: 2022-03-22

Last Posted Date: 2022-03-22

Lead Sponsor: Fudan University

Target Recruit Count: 62

Registration Number: NCT05290337

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Paclitaxel
Drug: Cisplatin

First Posted Date: 2022-03-15

Last Posted Date: 2023-07-13

Lead Sponsor: Fudan University

Target Recruit Count: 128

Registration Number: NCT05281003

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy